Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 303-314

  Nishida, Atsushi ^a   Hidaka, Kentaro ^a   Kanda, Toshihiro ^a   Imaeda, Hirotsugu ^a   Shioya, Makoto ^a   Inatomi, Osamu ^a   Bamba, Shigeki ^a   Kitoh, Katsuyuki ^a   Sugimoto, Mitsushige ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

chemokine; inflammatory bowel disease; interleukin 36

Indexed keywords

ACUTE PHASE PROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD3 ANTIGEN; CD68 ANTIGEN; COMPLEMENT COMPONENT C3; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CYTOKINE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 36 RECEPTOR; INTERLEUKIN 36ALPHA; INTERLEUKIN 36BETA; INTERLEUKIN 36GAMMA; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN C JUN; SMALL INTERFERING RNA; SYNDECAN 1; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; INTERLEUKIN 1; INTERLEUKIN 36, HUMAN;

ARTICLE; CD3+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CROHN DISEASE; DNA DETERMINATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; INTRACELLULAR SIGNALING; MONOCYTE; PATHOPHYSIOLOGY; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; UNINDEXED SEQUENCE; UPREGULATION; ADOLESCENT; ADULT; AGED; CELL CULTURE; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; HT-29 CELL LINE; IMMUNOPRECIPITATION; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CELLS, CULTURED; FOLLOW-UP STUDIES; HT29 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; INTESTINAL MUCOSA; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; YOUNG ADULT;

EID: 84955592969     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000654     Document Type: Article

References (49)

1. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev. 2013;252:164-182.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298-306.
4. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
5. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010; 42:332-337.
6. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
7. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
8. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 2014;49:785-798.
9. Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013;48: 315-321.
10. Kurishima A, Inaba M, Sakaguchi Y, et al. Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis. J Gastroenterol. 2014;49:1367-1377.
11. van de Veerdonk FL, Netea MG. New insights in the immunobiology of IL-1 family members. Front Immunol. 2013;4:167.
12. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999-1007.
13. Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol. 2013;4:181.
14. Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol. 2010;11:973.
15. Tripodi D, Conti F, Rosati M, et al. IL-36 a new member of the IL-1 family cytokines. J Biol Regul Homeost Agents. 2012;26:7-14.
16. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89-102.
17. Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004; 279:13677-13688.
18. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286: 42594-42602.
19. Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275:1169-1175.
20. Frey S, Derer A, Messbacher ME, et al. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis. 2013;72:1569-1574.
21. Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204:2603-2614.
22. Blumberg H, Dinh H, Dean C Jr, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol. 2010;185:4354-4362.
23. Dietrich D, Gabay C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol. 2014;10:639-640.
24. Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190: 2252-2262.
25. He Q, Chen HX, Li W, et al. IL-36 cytokine expression and its relationship with p38 MAPK and NF-kappaB pathways in psoriasis vulgaris skin lesions. J Huazhong Univ Sci Technolog Med Sci. 2013;33:594-599.
26. Mattii M, Ayala F, Balato N, et al. The balance between pro-and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members. Exp Dermatol. 2013;22: 813-819.
27. Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122: 3965-3976.
28. Kanazawa N, Nakamura T, Mikita N, et al. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol. 2013;40:749-751.
29. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131:2428-2437.
30. Lamacchia C, Palmer G, Rodriguez E, et al. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther. 2013;15:R38.
31. Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine. 2013;80: 449-453.
32. Gresnigt MS, Rosler B, Jacobs CW, et al. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 2013;43:416-426.
33. Ramadas RA, Ewart SL, Iwakura Y, et al. IL-36alpha exerts pro-inflammatory effects in the lungs of mice. PLoS One. 2012;7:e45784.
34. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sul-phasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
35. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterol-ogy. 1979;77:843-846.
36. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
37. Nishida A, Lau CW, Zhang M, et al. The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice. Gastroenterology. 2012;142:865-874 e862.
38. Shimada M, Andoh A, Hata K, et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol. 2002;168:861-868.
39. Vigne S, Palmer G, Martin P, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood. 2012;120:3478-3487.
40. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003-1018.
41. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014;10:44-56.
42. Muhr P, Zeitvogel J, Heitland I, et al. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol. 2011;165:189-193.
43. Johnston A, Xing X, Guzman AM, et al. IL-1F5,-F6,-F8, and-F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186: 2613-2622.
44. Magne D, Palmer G, Barton JL, et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibro-blasts and articular chondrocytes. Arthritis Res Ther. 2006;8:R80.
45. Ramadas RA, Ewart SL, Medoff BD, et al. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol. 2011;44:134-145.
46. Chustz RT, Nagarkar DR, Poposki JA, et al. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2011;45:145-153.
47. Yang SK, Choi MS, Kim OH, et al. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patients with ulcerative colitis: regulation by corticosteroids. Am J Gastroenterol. 2002; 97:126-132.
48. Zhong W, Kolls JK, Chen H, et al. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front Biosci. 2008;13: 1654-1664.
49. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217-242.